Home » $100 BILLION BURNS HOLE IN DRUG FIRMS' POCKETS
$100 BILLION BURNS HOLE IN DRUG FIRMS' POCKETS
Big pharma's appetite for biotech deals, already fueled by a need to supplement
weakened pipelines and replace products coming off patent, is expected to surge
this year as a handful of companies seek to reinvest nearly $100 billion in
repatriated profits.
MSNBC
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May